Recruiting
Phase 2

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Sponsor:

Emory University

Code:

NCT05039073

Conditions

Recurrent Classic Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Brentuximab Vedotin

Hematopoietic Cell Transplantation

Nivolumab

Quality-of-Life Assessment

Questionnaire Administration

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information